



Tipifarnib

Catalog No: tcsc0475

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 192185-72-1
Formula: $C_{27}^{H}_{22}^{Cl}_{2}^{N}_{4}^{O}$
Pathway: Metabolic Enzyme/Protease
Target: Farnesyl Transferase
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: IND 58359;R115777
Observed Molecular Weight: 489.4





Product Description

Tipifarnib is a potent and specific **farnesyltransferase (FTase)** inhibitor with **IC**₅₀ of 0.6 nM, and the anti-proliferative effects are most prominent in H-ras or N-ras mutant cells.

IC50 & Target: IC50: 0.6 nM (FTase)

In Vitro: Tipifarnib (5 μM) leads the percentage of apoptotic cells significantly higher in drug-treated compared to DMSO-treated LGL T-cells. Using T-cells from healthy donors, tipifarnib reduces the percentage of IFNγ-positive cells in a time-dependent manner. Tipifarnib reduces the amount of activated Ras in precipitates compared to DMSO^[2]. Tipifarnib exerts selective in vitro toxicity against clonal MDS hematopoiesis at concentrations less than 10 nM the effect being more prominent in white cell progenitors. This action is not due to apoptosis induction as both normal and MDS progenitors displays equivalent DiOC3 and annexin V expression up to 72 hours after exposure to Tipifarnib^[3]. Combining Tipifarnib with 10 nM 4-OH-tamoxifen in the presence of E2 reduces the IC₅₀ 8-fold from 400 to 50 nM^[4]. Tipifarnib induces apoptosis in U937 cells^[5]. In addition, Tipifarnib inhibits isolated human farnesyltransferase for a lamin B peptide and for the K-RasB peptide with IC₅₀ of 0.86 nM and 7.9 nM, respectively^[6].

In Vivo: Tipifarnib has the light of the modest toxicity in patients and the potent reduction of graft-versus-host disease in mice, and it could help to reduce graft-versus-host disease significantly without having a negative impact on immune reconstitution^[1]. Combined therapy with tamoxifen and Tipifarnib (50 mg/kg, p.o.) produces greater tumor growth inhibition when compared with either drug alone. E2 deprivation and Tipifarnib in combination results in greater growth inhibition than either E2 deprivation or Tipifarnib alone. The combination of tamoxifen and Tipifarnib results in significantly lower Ki-67 compared with either tamoxifen or Tipifarnib alone. Tipifarnib alone also reduces the CTI compared with control. The combination of tamoxifen and Tipifarnib or Tipifarnib coupled with E2 withdrawal is most effective at lowering the CTI (0.8 and 0.7, respectively), which may account for the decrease in tumor volume^[4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!